Evaxion Biotech A/S

EVAX | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.27

+$0.06 (+1.87%)

Sep 22, 2026, 11:33 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.87%

(1D)

Rating

Updated: Sep 2, 2026

38.5

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $20.67M

1D Range

3.18 3.31

52W Range

2.77 12.15

Valuation (TTM)

PE -0.52

PB 2.13

EV/EBITDA -1.35

Valuation (NTM)

Forward PE 84.28

Forward PEG 0.01

Price Target $11.67

Cash Flow

FCF Yield 0.0%

SBC Adj. FCF Yield 0.0%

SBC Impact N/A

Margins

Gross Margin 100.0%

Operating Margin -116.0%

FCF Margin 0.0%

Growth (CAGR)

Revenue 3Y | 5Y 98.9% | 83.0%

Dil EPS 3Y | 5Y 53.2% | 44.8%

FCF 3Y | 5Y 150.0% | 70.2%

Returns

ROA -44.6%

ROE -61.4%

ROIC -46.7%

Financial Health

Net Cash

$8.34M

Current Ratio 5.06

Interest Coverage -11.89

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and vira...

Sector Healthcare

Industry Biotechnology

Employees 46

IPO Date Feb 4, 2021

Website evaxion.ai

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$10

Upside

+205.81%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞